ABSTRACT
Background Effective management of type 2 diabetes is an increasing challenge for health services globally. Integrated care, targeted at increasing capacity in primary care for earlier intervention in type 2 diabetes, may reduce adverse health outcomes, with benefits accrued over time. This protocol aims to describe a causal approach for the evaluation of a specialist-led integrated model of care delivered in Australian general practices, using linked administrative health data.
Methods This protocol outlines an observational cohort study using the Lumos data asset (New South Wales Health), linking general practice and hospital data. It follows the target trial framework, emulating a parallel cluster-randomised trial, and applies the estimands framework proposed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. It describes the data structure and statistical analysis plan required for causal inference. The primary causal estimand is the effect of the Diabetes Alliance Program Plus, an integrated care intervention, on all-cause hospitalisation rates for adults actively attending general practice with current or newly diagnosed type 2 diabetes over a 5-year follow-up period.
Discussion This protocol applies the target trial framework to emulate a parallel cluster-randomized trial of the Diabetes Alliance Program Plus using linked administrative data. This approach addresses confounding and selection bias inherent in observational evaluations of practice-level interventions and will generate robust real-world evidence to inform policy regarding type 2 diabetes management in primary care settings.
Trial registration ACTRN12622001438741; 10th November 2022, retrospectively registered: https://www.anzctr.org.au/ACTRN12622001438741.aspx.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Diabetes Alliance Program Plus (DAP+) and this work is supported by a philanthropic gift from the Colonial Foundation, administered by the Hunter Medical Research Institute. Joshua Dizon is supported by an Australian Government Research Training Program (RTP) scholarship administered through the University of Newcastle Strategic Engagement Scheme.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Diabetes Alliance Program Plus has ethics approval from the Hunter New England Human Research Ethics Committee (2024/ETH01649), registered with the University of Newcastle (R-2024-0073). The Lumos data asset has ethics approval from the Population Health Services Research Ethics Committee (2019/ETH00660) with a waiver of individual participant consent for approved secondary data uses.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Major revisions to overall manuscript. Supplemental files updated.
